key: cord-0706544-0yqwly55
authors: Hernandez, M. M.; Banu, R.; Shrestha, P.; Patel, A.; Chen, F.; Cao, L.; Fabre, S.; Tan, J.; Lopez, H.; Chiu, N.; Shifrin, B.; Zapolskaya, I.; Flores, V.; Lee, P. Y.; Castaneda, S.; Ramirez, J. D.; Jhang, J.; Osorio, G.; Gitman, M. R.; Nowak, M. D.; Reich, D. L.; Cordon-Cardo, C.; Sordillo, E. M.; Paniz Mondolfi, A. E.
title: Comparison of SARS-CoV-2 detection in Saliva by real-time RT-PCR and RT-PCR/MALDI-TOF Methods
date: 2021-03-12
journal: nan
DOI: 10.1101/2021.03.11.21253234
sha: 41f3c3c8b131eb518e1d3eb40071a926cfc16cfc
doc_id: 706544
cord_uid: 0yqwly55

The coronavirus disease 2019 (COVID-19) pandemic has accelerated the need for rapid implementation of diagnostic assays for detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in respiratory specimens. While multiple molecular methods utilize nasopharyngeal specimens, supply chain constraints and need for easier and safer specimen collection warrant alternative specimen types, particularly saliva. Although saliva has been found to be a comparable clinical matrix for detection of SARS-CoV-2, evaluations of diagnostic and analytic performance across platforms for this specimen type are limited. Here, we compared two methods for SARS-CoV-2 detection in saliva: the Roche cobas(R) 6800/8800 SARS-CoV-2 real-time RT-PCR Test and the Agena Biosciences MassARRAY(R) SARS-CoV-2 Panel/MassARRAY(R) System. Overall, both systems had high agreement with one another, and both demonstrated high diagnostic sensitivity and specificity when compared to matched patient upper respiratory specimens. We also evaluated the analytical sensitivity of each platform and determined the limit of detection of the Roche assay was four times lower than that of Agena for saliva specimens (390.6 v. 1,562.5 copies/mL). Furthermore, across individual target components of each assay, T2 and N2 targets had the lowest limits of detection for each platform, respectively. Together, we demonstrate that saliva represents an appropriate specimen for SARS-CoV-2 detection in two technologies that have high agreement and differ in analytical sensitivities overall and across individual component targets. The addition of saliva as an acceptable specimen and understanding the sensitivity for testing on these platforms can further inform public health measures for screening and detection to combat the COVID-19 pandemic.

detected, results were interpreted as positive if at least two targets were detected or negative if less than 110 two targets were detected. If MS2 IC was not detected and no targets were detected, the result was 111 interpreted as invalid and required rerunning of the specimen. 112

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

The limit of detection (LoD) was determined across both platforms using known concentrations 114 of a SARS-CoV-2 standard spiked into saliva clinical matrix. 115

Briefly, an in-house SARS-CoV-2 standard was generated by pooling 59 NP specimens that 116 previously tested positive at MSHS CML (average T1 cycle threshold (Ct) = 17.53, average T2 Ct = 117 17.59). To quantitate the standard, three dilutions of the pooled sample were made (e.g., 1:50,000 (D1), 118 1:100,000 (D2), 1:200,000 (D3)) and run alongside serial dilutions of a commercially available standard 119 (ZeptoMetrix, NATSARS(COV2)-ERC) on the Roche platform which has EUA from the FDA for SARS-120

CoV-2 detection in NP specimens. All reactions were run in triplicate and SARS-CoV-2-negative NP 121 matrix served as the diluent. Concentrations of each standard dilution was determined by extrapolation 122 from standard curves generated across T1 and T2 targets (Fig. S1 ) for each dilution. The stock 123 concentration was, in turn, calculated as the average of the extrapolated stock concentrations determined 124 at each dilution. Aliquots (50 μL) of this stock measurand were stored at -80°C to prevent multiple freeze-125 thaw cycles. 126

To simulate collection of saliva for testing, saliva from healthy donors was combined in equal 127 parts with VTM and spiked with the SARS-CoV-2 measurand. Serial dilutions of the spiked saliva-VTM 128 specimens were generated in 50-mL conical vials (Corning 352070) over a range of 3,125.0 -97.7 129 copies/mL (cp/mL) and 12,500 -195.3 cp/mL for testing on the Roche and Agena platforms, respectively. 130

For each platform, ten replicates of each dilution were generated as well as ten replicates of saliva-VTM 131 spiked with the SARS-CoV-2-negative NP diluent to serve as negative controls. Spiked saliva-VTM 132 specimens were processed and run as described above. SARS-CoV-2 was not detected in any of the 133 negative controls and all results were valid across both platforms. 134 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 For each platform, the LoD of each overall assay and each target were determined. The 135 experimental LoD represents the lowest concentration with 95% detection. The probit LoD (and 95% 136 fiduciary confidence intervals) was determined by 95% detection based on a probit regression model. 137

For comparison of outcomes across both platforms, percent agreement and Cohen's kappa ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint

Sixty patients who underwent testing for SARS-CoV-2 by NAAT (NP or AN) at MSHS CML 149 were provided with sterile containers for submission of saliva specimens within 48 hours of diagnosis. 150

Saliva specimens were immediately processed and run side-by-side on the Roche and Agena platforms. 151

When compared to paired NP or AN specimens, both platforms had equivalent sensitivities (97.14%, CI: 152 85.08-99.93%) and specificities (100%, CI: 86.28-100%) for saliva specimens. 153

The Roche platform detected SARS-CoV-2 RNA in 34/60 saliva specimens ( We next systematically measured the limit of detection (LoD) of each platform and the component 168 targets. We generated a SARS-CoV-2 standard from high-titer positive NP specimens collected from 169 MSHS patients diagnosed at CML. The titer of the in-house standard was determined by extrapolating 170 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint concentrations of three dilutions run alongside serial dilutions of a commercial SARS-CoV-2 standard on 171 the Roche platform (Fig. S1 ). This had the benefit of accounting for any variation in extraction efficiency. 172

The in-house standard was spiked into saliva matrix collected from healthy donors and ten 173 replicates of serial dilutions were run side-by-side on each platform. On the Agena platform, the 174 experimental LoD was determined to be 1,562.5 cp/mL (Table 2) which is slightly lower than the LoD 175 reported by manufacturers for NP clinical matrix (2,500 cp/mL) (19). Across the five different Agena 176 targets, the most sensitive target was the N2 target (1,562.5 cp/mL) followed by the N1 target (3,125 177 cp/mL) ( Table 2 , Fig. 2A ). The least sensitive was the Orf1ab target whose LoD could not be determined 178

from the range of concentrations tested. This reflected a gradient in performance across the individual 179 components on the Agena platform. 180

On the Roche platform, the experimental LoD was lower than that of Agena at 390.6 cp/mL. The 181

Ct values for these saliva specimens demonstrated a linear correlation with the corresponding 182 concentrations across both T1 (R 2 =0.9760, p=0.0016) and T2 (R 2 =0.9534, p=0.008) (Fig. 2B) . Overall, 183 T2 Ct values were higher than T1 Ct values for specimens at the same concentration (p<0.01) which is 184 consistent with previous reports for NP specimens (21, 22) . While the experimental LoD for T1 and T2 185 targets were determined equivalent, probit analyses suggest the LoD of T2 is, in fact, lower (228.6 cp/mL). 186

However, the fiduciary confidence interval for this value is broad (151.4-3.7x10 10 ) given that the 187 concentration at which no specimens were detected was not determined in our study. 188 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint

Saliva represents an attractive alternative specimen type for SARS-CoV-2 testing given its limited 190 invasiveness, ability to be self-collected, and reduced need for limited supplies A number of groups have 191 demonstrated that saliva is an acceptable and sensitive specimen type when compared to other upper 192 respiratory (e.g., NP, AN, OP) specimens (5, 8, 9, (12) (13) (14) . However, analytical performance of this 193 specimen type has yet to be evaluated across the multitude of platforms utilized. In this study, we 194 demonstrate the utility of saliva as a diagnostic specimen across the Roche and Agena platforms. Saliva 195 specimens collected within two days are equivocally sensitive and specific across both methods when 196 compared to matched NP or AN specimens. 197 It is important to note that these two platforms tested are distinguished from each other by their 198 technologic basis and their molecular targets. The Roche platform is like most of the current SARS-CoV-199 2 molecular diagnostic assays in that it utilizes real-time RT-PCR for detection. However, the Agena 200 platform utilizes mass spectrometry to detect targeted amplicons produced by RT-PCR. While distinct in 201 platform technology, our findings demonstrate comparable diagnostic capabilities of both platforms for 202 detection of SARS-CoV-2 nucleic acids in clinical saliva specimens (Table 1) . 203

The platforms we evaluated also differed by SARS-CoV-2 viral targets probed. In contrast to the 204 Roche platform, which is based on two target amplicons (SARS-CoV-2 Orf1ab (T1) and pan-Sarbecovirus 205 E genes (T2)), the Agena platform probes for five targets across two viral genes (3 targets in the 206 nucleocapsid gene (N1, N2, N3), 2 targets in the Orf1ab gene (ORF1, Orf1ab)). This redundancy in viral 207 targets is required to ensure robust sensitivity. When we assessed analytic performance of each target 208 across the clinical saliva specimens, we observed variation in target performance with decreasing viral 209 titers (e.g., Ct values), particularly within the Agena platform (Fig. 1) . Specifically, the number of Agena 210 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint targets detected progressively dropped with decreasing concentration. This suggested inherent analytic 211 differences in the component targets that warrant further investigating. 212

In order to effectively utilize saliva as a clinical specimen for SARS-CoV-2 testing, it is essential 213 to characterize the analytical sensitivity for each diagnostic platform. Most studies have yet to evaluate 214 the LoD across platforms in a standardized method for saliva specimens (reviewed in (6)). Moreover, 215 analytic sensitivity of component targets are often reported as those described by manufacturers or are not 216 systematically evaluated, reported, nor compared across platforms (6, 7, 23-25). Our study demonstrates 217 a greater sensitivity in the Roche platform for saliva specimens overall (Fig. 2) . We also demonstrate that 218 across both platforms, there are some targets which are more sensitive than others such as N2 in Agena 219 and T2 in Roche (Fig. 2, Table 2 ). These metrics are vital as they can inform how diagnostic labs address 220 new circulating viral variants that have mutations that may interfere with multiple detection methods. 221

Our study does have limitations in that our saliva collection methods did not occur at one time 222 point but rather at any point in the day within two days of initial NP/AN collection. While the utility of 223 standardized collection methods (e.g., early morning collection) remain to be further clarified, this is not 224 a variable we controlled in this study. In addition, we utilized a pooled positive NP specimen to serve as 225 our analyte to assess sensitivity. As a result, the sensitivities measured are based on a potentially 226 heterogenous mixture of viral variants. We addressed this by pooling specimens isolated from two 227 consecutive days to ensure a sampling of the predominant circulating clade virus at the given time period. 228

Overall, we demonstrate comparable analytical performance across two unique diagnostic 229 platforms for detection of SARS-CoV-2 nucleic acids in saliva specimens. Given the continued spread 230 and rise of new SARS-CoV-2 variants, there is a critical need to understand the analytic capabilities of 231 these technologies. This is especially relevant in large-scale screening efforts where saliva has the 232 potential to be further exploited for its utility as a clinical specimen. This greater understanding of assay 233 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 and target sensitivity is essential to informing both effective detection efforts and broader public health 234 measures to ultimately quell the COVID-19 pandemic. 235 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

We thank the members of the MSHS CML for providing any assistance when needed throughout this 237 study. We also would like to thank the patients and healthy donors for providing specimens to complete 238 this study. 

The authors have no conflicts or competing interests to disclose. 250 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint Overall 10/10 10/10 10/10 10/10 1/10 0/10 0/10 0/10 1562.5 NA NA N1

10/10 10/10 10/10 9/10 2/10 0/10 0/10 0/10 3125.0 1745.5 (1336, 4069) N2

10/10 10/10 10/10 10/10 1/10 0/10 0/10 0/10 1562.5 NA NA N3

10/10 10/10 4/10 1/10 0/10 0/10 0/10 0/10 6250.0 5257.8 (3989, 12801) ORF1 10/10 10/10 8/10 8/10 0/10 0/10 0/10 0/10 6250.0 3544.7 (2502, 8161) Orf1ab 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 >12500 NA NA a Experimental (Exp) LoD determined by concentration at which detection is ≥95% 339 b LoD determined by probit analysis. "NA" reflects inability to perform probit analyses due to lack of sufficient probit points 340 c 95% fiduciary confidence interval

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 *, p<0.05; **, p<0.01; ***, p<0.001, ****, p<0.0001) based on student's t-test or Mann-Whitney non-349 parametric test depending on whether data was normally distributed (see Methods). 350

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 22 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint concentration is the percent of replicates detected by T1 or T2 targets. 357

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253234 doi: medRxiv preprint 26 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection 253 of SARS-CoV-2 in Clinical Laboratories

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-279

Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis 297 of asymptomatic and mild COVID-19 infection

Considerations for 299 diagnostic COVID-19 tests

Emerging technologies for diagnostics and drug delivery in the fight against 301

COVID-19 and other pandemics

Comparative Performance of SARS-CoV-2 Detection Assays 318

Using Seven Different Primer-Probe Sets and One Assay Kit

Evaluation of symptomatic patient saliva as a sample 321 type for the Abbott ID NOW COVID-19 assay

Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in 324 the community setting